ImageneBio, Inc. (IMA)
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
ImageneBio Inc
NASDAQ:IMAHealthcare · Biotechnology
+1.23%$4.10
AH$4.10+0.00%vs close
Mkt Cap$46.54M
Float10.96M
O/S11.35M
Vol
$ Vol
RVOL
Inst Own54.9%
SI0.6%
Earnings
Dilution
Financials Summary
Revenue$800K
Net Income-$45.35M
Total Assets$152.98M
Free Cash Flow-$47.84M
Debt & Equity
Debt 7%
Equity 93%
Total Debt$9.99M
Total Equity$133.14M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in IMA's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$152.98M
Liabilities$19.84M
Accounts Receivable$1.3M
Accounts Payable$1.44M
Inventory$0
PP&E (Net)$790K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $800K | $3.5M | $9.16M | $15.62M | $30.98M | $9.19M | $13.75M | $990K |
| YoY Growth | -77.1% | -61.8% | -41.3% | -49.6% | 237.0% | -33.1% | 1289.2% | - |
| Cost of Revenue | $1.03M | $1.53M | $1.02M | $64.32M | $47.11M | $44.85M | $24.94M | $38.99M |
| Gross Profit | -$233K | $1.97M | $8.14M | -$48.7M | -$16.12M | -$35.65M | -$11.19M | -$38M |
| Gross Margin | -29.1% | 56.4% | 88.9% | -311.8% | -52.0% | -387.8% | -81.3% | -3838.0% |
| Research and Development | $28.52M | $32.11M | $59.65M | $64.32M | $47.11M | $44.85M | $24.94M | $38.56M |
| Selling, General, and Administrative | $20.73M | $8.39M | $24.93M | $22.2M | $18.02M | $8.87M | $7.31M | $2.9M |
| Other | -$1.03M | -$1.53M | -$1.02M | -$64.32M | -$47.11M | -$44.85M | -$24.94M | $0 |
| Total Operating Expenses | $48.22M | $38.97M | $83.56M | $22.2M | $18.02M | $8.87M | $7.31M | $41.46M |
| Operating Income (EBIT) | -$48.45M | -$37M | -$75.42M | -$70.9M | -$34.14M | -$44.52M | -$18.49M | -$40.89M |
| Operating Margin | -6056.4% | -1057.1% | -823.3% | -454.0% | -110.2% | -484.2% | -134.5% | -4130.7% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $2.04M | $7.37M | $7.11M | $2.15M | $23K | $0 | $0 | $0 |
| Other Income (Expense) | $2.75M | $445K | $7.09M | $2.14M | $23K | $263K | $1.68M | $29K |
| Income Before Tax (EBT) | -$45.7M | -$36.55M | -$68.33M | -$68.77M | -$34.12M | -$44.26M | -$16.82M | -$40.87M |
| Income Tax Expense | -$350K | $13K | -$162K | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$45.35M | -$36.57M | -$68.17M | -$68.77M | -$34.12M | -$44.26M | -$16.82M | -$40.87M |
| Net Income Margin | -5668.6% | -1044.8% | -744.2% | -440.3% | -110.1% | -481.4% | -122.3% | -4127.8% |
| Supplementary Data | ||||||||
| EPS | -9.64 | -40.52 | -19.60 | -22.80 | -11.38 | -14.81 | -5.63 | -13.68 |
| Diluted EPS | -9.64 | -40.52 | -19.60 | -22.80 | -11.38 | -14.81 | -5.63 | -13.68 |
| Weighted Average OS | 5.43M | 1.19M | 3.48M | 3.02M | 3.00M | 2.99M | 2.99M | 2.99M |
| EBITDA | -$44.67M | -$35.03M | -$67.31M | -$68.01M | -$33.57M | -$44.22M | -$18.25M | -$40.44M |
| EBITDA Margin | -5583.3% | -1000.8% | -734.8% | -435.5% | -108.3% | -481.0% | -132.7% | -4085.2% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $34.97M | $39.39M | $119.89M | $59.92M | $232.22M | $162.49M | $82.08M | $18.16M |
| Short-Term Investments | $40.82M | $84.99M | $55.57M | $97.03M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $75.78M | $124.39M | $175.47M | $156.95M | $232.22M | $162.49M | $82.08M | $18.16M |
| Accounts Receivable | $1.3M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $63.21M | $2.78M | $1.15M | $964K | $629K | $1.54M | $1.27M | $582K |
| Total Current Assets | $140.29M | $127.17M | $178.66M | $160.01M | $236.52M | $165.97M | $85.2M | $19.98M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $790K | $4.23M | $8.02M | $8.46M | $8.98M | $1.56M | $769K | $696K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $2.39M | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $11.9M | $10.11M | $5.41M | $3.79M | $0 | $872K | $0 | $0 |
| Total Long-Term Assets | $12.69M | $14.34M | $13.43M | $12.25M | $11.36M | $2.44M | $769K | $696K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $152.98M | $141.51M | $192.09M | $172.26M | $247.88M | $168.4M | $85.97M | $20.68M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $1.44M | $897K | $2.07M | $2.09M | $2.38M | $2.12M | $935K | $2.27M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $9.16M | $17.1M | $20.62M | $20.68M | $126K |
| Other Current Liabilities | $7.53M | $1.75M | $3.4M | $5.11M | $2.83M | $2.2M | $1.16M | $126K |
| Total Current Liabilities | $11.23M | $10.78M | $14.21M | $21.5M | $27.19M | $28.33M | $24.3M | $3.82M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $7.02M | $0 | $0 | $0 | $0 | $0 | $0 | $62.58M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $7.68M | $35.14M | $44.27M | $116K |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $870K | $1.06M | $950K | $0 | $0 | $205.98M | $78.87M | $0 |
| Total Long-Term Liabilities | $8.6M | $4.8M | $8.13M | $3.79M | $12.81M | $241.12M | $123.14M | $62.69M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $19.84M | $15.58M | $22.34M | $25.29M | $40M | $269.45M | $147.44M | $66.52M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $62.58M |
| Common Stock | $11K | $48K | $48K | $36K | $36K | $3K | $3K | $19K |
| Retained Earnings | -$230.05M | -$331.62M | -$282.38M | -$214.22M | -$145.45M | -$111.34M | -$67.08M | -$50.27M |
| Comprehensive Income & Other | $87K | $68K | -$48K | -$763K | $0 | $0 | $0 | -$0 |
| Other Stockholders' Equity | $363.18M | $457.5M | $452.09M | $361.15M | $353.3M | $10.29M | $5.62M | $4.41M |
| Total Equity | $133.14M | $125.93M | $169.76M | $146.97M | $207.88M | -$101.05M | -$61.46M | -$45.84M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $152.98M | $141.51M | $192.09M | $172.26M | $247.88M | $168.4M | $85.97M | $20.68M |
| Supplementary Data | ||||||||
| Total Debt | $9.99M | $7.52M | $10.74M | $5.69M | $6.99M | $186K | $0 | $62.58M |
| Net Debt | -$24.97M | -$31.87M | -$109.16M | -$54.23M | -$225.23M | -$162.31M | -$82.08M | $44.42M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$52.4M | -$49.23M | -$68.17M | -$68.77M | -$34.12M | -$44.26M | -$16.82M | -$40.87M |
| Depreciation & Amortization | $1.03M | $1.53M | $1.02M | $751K | $544K | $300K | $243K | $422K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $15.39M | $5.29M | $0 | $7.53M | $5.18M | $1.8M | $1.17M | $314K |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | $0 | $0 | $0 | -$291K | $361K | $519K | -$1.33M | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $1.33M | $0 |
| Accounts Payable | -$2.82M | -$1.17M | -$2.87M | $0 | $0 | $0 | -$1.33M | $602K |
| Other Working Capital | -$16.37M | -$2.81M | -$18.8M | -$14.85M | -$33.39M | -$8.29M | $64.78M | -$544K |
| Total Working Capital Change | -$19.19M | -$3.98M | -$21.67M | -$15.14M | -$33.03M | -$7.77M | $63.45M | $58K |
| Other Non-Cash Items | $7.32M | $388K | $9.07M | $1.52M | $1.17M | $12.1M | -$121K | $29.02M |
| Net Cash from Operating | -$47.84M | -$46M | -$79.74M | -$74.11M | -$60.25M | -$37.83M | $47.93M | -$11.61M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $0 | -$414K | -$1.43M | -$1.76M | -$766K | -$316K | -$305K |
| Acquisitions | -$5.21M | $0 | $0 | $0 | $0 | $3.69M | $0 | $11.27M |
| Purchases of Investments | -$10.4M | -$88.3M | -$90.05M | -$216.34M | $0 | $0 | $0 | $0 |
| Sales of Investments | $9.8M | $60.46M | $154.61M | $118.48M | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | -$7.07M | $0 | $0 | $0 | $0 | $0 | $11.27M |
| Net Cash from Investing | -$5.81M | -$34.9M | $64.14M | -$99.28M | -$1.76M | $2.92M | -$316K | $10.97M |
| Financing Activities | ||||||||
| Debt Repaid | - | - | - | - | - | - | - | - |
| Common Stock Issuance | $65.84M | $0 | $37.56M | $0 | $131.3M | $0 | $16.32M | $0 |
| Common Stock Repurchases | $0 | $0 | -$663K | $0 | $0 | -$57K | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $54.63M | $0 | $39.09M | $1.09M | $582K | $70K | $25K | $0 |
| Net Cash from Financing | $135.47M | $0 | $75.98M | $1.09M | $131.74M | $116.18M | $16.32M | $0 |
| Forex Effect | $604K | $0 | -$406K | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $82.41M | -$80.91M | $59.98M | -$172.3M | $69.73M | $81.28M | $63.93M | -$639K |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$47.84M | -$46M | -$79.74M | -$74.11M | -$60.25M | -$37.83M | $47.93M | -$11.61M |
| Capital Expenditure | $0 | $0 | -$414K | -$1.43M | -$1.76M | -$766K | -$316K | -$305K |
| Free Cash Flow | -$47.84M | -$46M | -$80.16M | -$75.54M | -$62.01M | -$38.59M | $47.61M | -$11.91M |
| Cash at Beginning | $12.12M | $121.17M | $59.92M | $233.09M | $163.36M | $82.08M | $18.16M | $18.8M |
| Cash at End | $94.53M | $40.27M | $119.89M | $60.79M | $233.09M | $163.36M | $82.08M | $18.16M |